Nurix Therapeutics, Inc.

NASDAQ:NRIX

Biotechnology

Healthcare
$14.10 +0.85%

+$0.15 today

Market cap
$1.54B
Beta
1.87
P/E (TTM)
-6.4
EPS (TTM)
-$2.68
52W Low $8.20High $22.50

Volume 2.79M

Average 1.74M

NRIX Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Nurix Therapeutics, Inc.NASDAQ: NRIX

Research & Development · Q3 FY2026 · quarter ended Aug 2026

Research & development dips below year-ago levels

Q3 FY2026 research & development of $79.26M fell 8.0% year over year, behind the +10.2% change in trailing-twelve-month research & development. Sequentially, it fell 9.6% from the prior quarter. Over 3 fiscal years it compounded at +18.6% a year.

Context

  • Research & development amounted to 366.9% of revenue in FY2025, down 39.4 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -8.0% toward the trailing-twelve-month pace of +10.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterAug 2026
$79.26M-9.6% QoQ
Last fiscal yearNov 2025
$308.16M+39.0% YoY
LTMAug 2026
$331.95M+10.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-8.0%——
1 year+39.0%——
3-year CAGR+18.6%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
308.16M USD
Year-over-year change
+39.0%
4-year CAGR
+27.5%

Research & Development vs competitors

How NRIX compares with its peers on the latest reported figures

  • NRIX's LTM Aug 2026 research & development of $331.95M is the 3rd highest of the 8 companies compared; the peer median is $255.99M.
  • Its year-over-year change of +10.2% is the 6th highest of 8, against a peer median of +29.1%.
  • Research & development amounts to 47.3% of revenue for NRIX, versus a peer median of 291.9%.
NRIX Competitors Peer median
Research & Development for NRIX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RVMDRevolution Medicines, Inc.LTM Jun 2026$1.29B +68.1%+57.0%—
KYMRKymera Therapeutics, Inc.LTM Jun 2026$375.6M +29.1%+24.5%357.8%
NRIXNurix Therapeutics, Inc.LTM Aug 2026$331.95M +10.2%+18.6%47.3%
KURAKura Oncology, Inc.LTM Mar 2026$260.36M +37.3%+39.3%363.4%
SNDXSyndax Pharmaceuticals, Inc.LTM Mar 2026$255.99M +3.7%+29.7%117.9%
TNGXTango Therapeutics, Inc.LTM Sep 2026$152.48M +14.3%+7.7%—
CCCCC4 Therapeutics, Inc.LTM Mar 2026$101.77M -11.6%-4.0%291.9%
RIGLRigel Pharmaceuticals, Inc.LTM Mar 2026$36.54M +41.7%-17.9%12.2%
Peer median (excluding NRIX) $255.99M+29.1%+24.5%291.9%

Competitors are the stored peer set for NRIX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Nov 2021
FY2022
Nov 2022
FY2023
Nov 2023
FY2024
Nov 2024
FY2025
Nov 2025
Revenue29.75M38.63M76.99M54.55M83.98M
Cost of Revenue116.43M184.5M189.15M221.63M18.86M
Gross Profit(86.68M)(145.87M)(112.16M)(167.08M)65.12M
Gross Margin-291.4%-377.6%-145.7%-306.3%77.5%
Research & Development116.43M184.5M189.15M221.63M308.16M
Selling, General & Admin31.2M38M42.9M45.94M52.74M
Operating Expenses31.2M38M42.9M45.94M350.79M
Depreciation & Amortization6.08M10.81M13.65M16.43M18.86M
EBITDA(110.98M)(169.55M)(130.29M)(176.87M)(244.84M)
EBITDA Margin-373.0%-438.9%-169.2%-324.2%-291.5%
Operating Income(117.89M)(183.87M)(155.06M)(213.03M)(285.67M)
Operating Margin-396.3%-476.0%-201.4%-390.5%-340.2%
Interest Income823K3.51M11.12M19.73M21.97M
Interest Expense00000
Other Income / Expenses823K3.51M11.12M19.73M21.97M
Income Before Tax(117.06M)(180.36M)(143.95M)(193.3M)(263.7M)
Pre-Tax Margin-393.5%-466.9%-187.0%-354.4%-314.0%
Income Tax Expense131K00270K760K
Net Income(117.19M)(180.36M)(143.95M)(193.57M)(264.46M)
Net Margin-393.9%-466.9%-187.0%-354.9%-314.9%
EPS (Basic)(2.73)(3.71)(2.65)(2.88)(3.05)
EPS (Diluted)(2.73)(3.71)(2.65)(2.88)(3.05)
Weighted Avg Shares42.9M48.61M54.34M67.12M86.67M
Weighted Avg Shares (Diluted)42.9M48.61M54.34M67.12M86.67M

Nurix Therapeutics, Inc.

NASDAQ:NRIX

Intrinsic Alpha fair value

Locked

Current Price

$14.10

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.